|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACMSD |
Gene summary for ACMSD |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACMSD | Gene ID | 130013 |
| Gene name | aminocarboxymuconate semialdehyde decarboxylase | |
| Gene Alias | ACMSD | |
| Cytomap | 2q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | A0A0S2Z681 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 130013 | ACMSD | NAFLD1 | Human | Liver | NAFLD | 7.47e-17 | 1.42e+00 | -0.04 |
| 130013 | ACMSD | S43 | Human | Liver | Cirrhotic | 3.07e-05 | -1.45e-01 | -0.0187 |
| 130013 | ACMSD | HCC1_Meng | Human | Liver | HCC | 7.36e-39 | -1.24e-01 | 0.0246 |
| 130013 | ACMSD | HCC2_Meng | Human | Liver | HCC | 9.51e-08 | -2.06e-01 | 0.0107 |
| 130013 | ACMSD | cirrhotic1 | Human | Liver | Cirrhotic | 8.52e-03 | -1.75e-01 | 0.0202 |
| 130013 | ACMSD | cirrhotic2 | Human | Liver | Cirrhotic | 9.39e-05 | -2.01e-01 | 0.0201 |
| 130013 | ACMSD | HCC1 | Human | Liver | HCC | 1.75e-13 | 6.56e-01 | 0.5336 |
| 130013 | ACMSD | Pt14.d | Human | Liver | HCC | 1.36e-03 | -1.98e-01 | 0.0143 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00463953 | Liver | NAFLD | carboxylic acid catabolic process | 73/1882 | 236/18723 | 4.16e-19 | 1.22e-15 | 73 |
| GO:00160544 | Liver | NAFLD | organic acid catabolic process | 73/1882 | 240/18723 | 1.20e-18 | 2.34e-15 | 73 |
| GO:00442825 | Liver | NAFLD | small molecule catabolic process | 91/1882 | 376/18723 | 8.96e-16 | 1.31e-12 | 91 |
| GO:00194396 | Liver | NAFLD | aromatic compound catabolic process | 102/1882 | 467/18723 | 2.29e-14 | 1.91e-11 | 102 |
| GO:19013616 | Liver | NAFLD | organic cyclic compound catabolic process | 105/1882 | 495/18723 | 7.04e-14 | 5.15e-11 | 105 |
| GO:00160535 | Liver | NAFLD | organic acid biosynthetic process | 77/1882 | 316/18723 | 1.03e-13 | 6.69e-11 | 77 |
| GO:00463945 | Liver | NAFLD | carboxylic acid biosynthetic process | 75/1882 | 314/18723 | 6.37e-13 | 3.39e-10 | 75 |
| GO:00442707 | Liver | NAFLD | cellular nitrogen compound catabolic process | 93/1882 | 451/18723 | 1.04e-11 | 4.34e-09 | 93 |
| GO:00467006 | Liver | NAFLD | heterocycle catabolic process | 92/1882 | 445/18723 | 1.16e-11 | 4.52e-09 | 92 |
| GO:0009063 | Liver | NAFLD | cellular amino acid catabolic process | 36/1882 | 110/18723 | 6.56e-11 | 1.99e-08 | 36 |
| GO:00065203 | Liver | NAFLD | cellular amino acid metabolic process | 63/1882 | 284/18723 | 1.14e-09 | 2.17e-07 | 63 |
| GO:19016053 | Liver | NAFLD | alpha-amino acid metabolic process | 46/1882 | 195/18723 | 2.74e-08 | 2.86e-06 | 46 |
| GO:00091177 | Liver | NAFLD | nucleotide metabolic process | 85/1882 | 489/18723 | 3.31e-07 | 2.18e-05 | 85 |
| GO:00723303 | Liver | NAFLD | monocarboxylic acid biosynthetic process | 46/1882 | 214/18723 | 5.06e-07 | 3.07e-05 | 46 |
| GO:00620125 | Liver | NAFLD | regulation of small molecule metabolic process | 63/1882 | 334/18723 | 6.55e-07 | 3.79e-05 | 63 |
| GO:00067537 | Liver | NAFLD | nucleoside phosphate metabolic process | 85/1882 | 497/18723 | 6.69e-07 | 3.83e-05 | 85 |
| GO:1901606 | Liver | NAFLD | alpha-amino acid catabolic process | 25/1882 | 87/18723 | 8.67e-07 | 4.60e-05 | 25 |
| GO:0009074 | Liver | NAFLD | aromatic amino acid family catabolic process | 8/1882 | 16/18723 | 6.30e-05 | 1.37e-03 | 8 |
| GO:00436483 | Liver | NAFLD | dicarboxylic acid metabolic process | 22/1882 | 96/18723 | 1.73e-04 | 3.08e-03 | 22 |
| GO:0062014 | Liver | NAFLD | negative regulation of small molecule metabolic process | 21/1882 | 102/18723 | 1.09e-03 | 1.27e-02 | 21 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa003802 | Liver | Cirrhotic | Tryptophan metabolism | 22/2530 | 42/8465 | 1.85e-03 | 8.37e-03 | 5.16e-03 | 22 |
| hsa0038011 | Liver | Cirrhotic | Tryptophan metabolism | 22/2530 | 42/8465 | 1.85e-03 | 8.37e-03 | 5.16e-03 | 22 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACMSD | SNV | Missense_Mutation | rs267598886 | c.581N>A | p.Gly194Glu | p.G194E | Q8TDX5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| ACMSD | SNV | Missense_Mutation | rs267598886 | c.581N>A | p.Gly194Glu | p.G194E | Q8TDX5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACMSD | SNV | Missense_Mutation | rs144757487 | c.517N>A | p.Val173Met | p.V173M | Q8TDX5 | protein_coding | deleterious(0) | probably_damaging(0.924) | TCGA-ZJ-AAX4-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACMSD | SNV | Missense_Mutation | c.391N>T | p.Arg131Cys | p.R131C | Q8TDX5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3850-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| ACMSD | SNV | Missense_Mutation | c.749N>G | p.Asp250Gly | p.D250G | Q8TDX5 | protein_coding | deleterious(0.01) | benign(0.089) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| ACMSD | SNV | Missense_Mutation | rs372245923 | c.310N>A | p.Val104Ile | p.V104I | Q8TDX5 | protein_coding | tolerated(0.07) | benign(0.038) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACMSD | SNV | Missense_Mutation | c.922A>G | p.Met308Val | p.M308V | Q8TDX5 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ACMSD | SNV | Missense_Mutation | novel | c.768N>T | p.Lys256Asn | p.K256N | Q8TDX5 | protein_coding | tolerated(0.11) | benign(0.007) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| ACMSD | SNV | Missense_Mutation | rs267598885 | c.175N>T | p.Arg59Cys | p.R59C | Q8TDX5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| ACMSD | SNV | Missense_Mutation | c.810N>A | p.Asp270Glu | p.D270E | Q8TDX5 | protein_coding | deleterious(0.04) | benign(0.413) | TCGA-AG-3742-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |